Earlier, the company stated: “Nektar (NKTR) Therapeutics announced it will host an investor call and live webcast to review topline results from the 36-week induction treatment period in the ongoing Phase 2b REZOLVE-AA clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for severe-to-very-severe alopecia areata on Tuesday, December 16, 2025 at 8:00 am ET / 5:00 am PT.” Shares of Nektar are up 10% afterhours at $58.76.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Coterra, Ovintiv, Nektar, Co-Diagnostics, Fluence: Trending by Analysts
- Autodesk upgraded, Nio downgraded: Wall Street’s top analyst calls
- Nektar price target raised to $121 from $99 at Jefferies
- Citi starts Nektar with Buy, opens ‘positive catalyst watch’
- Nektar Therapeutics Announces Chief Legal Officer Departure